IMUNON enters into CRADA to evaluate DNA-based Lassa virus vaccine candidates
The clinical-stage biotechnology company has entered into a cooperative research and development agreement with NIAID to evaluate the efficacy of two IMUNON DNA-based Lassa virus vaccine candidates